Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Q: Im trying to conceive
Growing diabetes and obesity prevalence creates vast market opportunities, especially with rising patient awareness and acceptance of advanced therapies
These systems remove guesswork about needle selection and ensure consistent quality
Lilly has the following drugs in launch and late phase programs: Tirzepatide Orforglipron Eloralintide Retatrutide Brenipatide These products, along with six additional clinical stage programs and 34 discovery programs, have the potential to help 1 billion people across the following indications: Obesity Diabetes Obstructive sleep apnea Pain Cardiovascular Renal Hepatic During the Q&A portion of the presentation, Ricks responded to a question about his key takeaways from 2025 by saying, We think about both market growth and Lily's position within the US market
Retrieved 2007-11-23
US$ 25.17
US$ 21.31
US$ 21.60
US$ 21.58
US$ 25.23
US$ 25.84
US$ 28.02
US$ 22.22
